Moderna confirms COVID-19 vaccine supply agreement with MOH

The vaccine has a 94.1% efficacy rate against COVID-19.

Messenger RNA-pioneering biotechnology company Moderna has announced that it has secured an agreement with Singapore’s Ministry of Health to supply the country with Moderna’s vaccine candidate against COVID-19, mRNA-1273.

“We continue to advance the clinical development of mRNA-1273 and the recent positive primary efficacy analysis from our Phase 3 COVE study is an encouraging step forward as we work together to address this global health emergency by delivering a vaccine to the people of Singapore and around the world,” said Moderna’s CEO Stéphane Bancel in a statement.

Data from the Phase COVE study, which involved 30,000 participants, has shown an efficacy rate against COVID-19 at 94.1% and against severe COVID-19 at 100%. “Efficacy was consistent across age, race and ethnicity, and gender demographics in the 196 observed cases of COVID-19,” Moderna noted.

The Phase 3 COVE study is continuously monitored by an independent National Institutes of Health-appointed Data Safety Monitoring Board.

The most common adverse reactions were injection site pain, erythema or redness, fatigue, myalgia, arthralgia, and headache. These adverse reactions were reported to increase “in frequency and severity in the mRNA-1273 group after the second dose.”

Moderna plans to submit data from the Phase 3 COVE study to a peer-reviewed publication, the company added.